Deficits in brain function that are associated with aging and age-related diseases benefit
very little from currently available therapies, suggesting a better understanding of the …

Phosphodiesterase inhibitors (PDE-Is) enhance cAMP and/or cGMP signaling via reducing
the degradation of these cyclic nucleotides. Since both cAMP and cGMP signaling are …

Quercetin has been identified as a promising compound with a neuroprotective potential
against age-related neurodegenerative diseases such as Alzheimer's disease (AD) …

Alzheimer's disease (AD) is one of the greatest public health challenges.
Phosphodiesterases (PDEs) are a superenzyme family responsible for the hydrolysis of two …

Memory deficit is a marker of Alzheimer's disease (AD) that has been highly associated with
the dysfunction of cyclic GMP (cGMP) signaling and an ongoing inflammatory process …

Astrocytes, as the most abundant glial cells in the central nervous system, are tightly
integrated into neural networks and participate in numerous aspects of brain physiology and …

Alzheimer's disease (AD) is a widespread and devastating progressive neurodegenerative
disease. Disease-modifying treatments remain beyond reach, and the etiology of the …

Tau accumulation is a core component of Alzheimer's disease and other neurodegenerative
tauopathies. While tau's impact on neurons is a major area of research, the effect of …

Increasing human life expectancy prompts the development of novel remedies for cognitive
decline: 44 million people worldwide are affected by dementia, and this number is predicted …

Abstract Alzheimer's disease (AD), one of the greatest threats to human health, is
characterized by declined cognition and changed behavior. Cyclic adenosine …